TY - JOUR
T1 - (−)-Epicatechin inhibits development of dilated cardiomyopathy in δ sarcoglycan null mouse
AU - De los Santos, S.
AU - Palma-Flores, C.
AU - Zentella-Dehesa, A.
AU - Canto, P.
AU - Coral-Vázquez, R. M.
N1 - Publisher Copyright:
© 2018 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University
PY - 2018/11
Y1 - 2018/11
N2 - Background and aims: Several studies propose that (−)-epicatechin, a flavonol present in high concentration in the cocoa, has cardioprotective effects. This study aimed to evaluate the impact of (−)-epicatechin on the development of dilated cardiomyopathy in a δ sarcoglycan null mouse model. Methods and results: δ Sarcoglycan null mice were treated for 15 days with (−)-epicatechin. Histological and morphometric analysis of the hearts treated mutant mice showed significant reduction of the vasoconstrictions in the coronary arteries as well as fewer areas with fibrosis and a reduction in the loss of the ventricular wall. On the contrary, it was observed a thickening of this region. By Western blot analysis, it was shown, and increment in the phosphorylation level of eNOS and PI3K/AKT/mTOR/p70S6K proteins in the heart of the (−)-epicatechin treated animals. On the other hand, we observed a significantly decreased level of the atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) heart failure markers. Conclusion: All the results indicate that (−)-epicatechin has the potential to prevent the development of dilated cardiomyopathy of genetic origin and encourages the use of this flavonol as a pharmacological therapy for dilated cardiomyopathy and heart failure diseases.
AB - Background and aims: Several studies propose that (−)-epicatechin, a flavonol present in high concentration in the cocoa, has cardioprotective effects. This study aimed to evaluate the impact of (−)-epicatechin on the development of dilated cardiomyopathy in a δ sarcoglycan null mouse model. Methods and results: δ Sarcoglycan null mice were treated for 15 days with (−)-epicatechin. Histological and morphometric analysis of the hearts treated mutant mice showed significant reduction of the vasoconstrictions in the coronary arteries as well as fewer areas with fibrosis and a reduction in the loss of the ventricular wall. On the contrary, it was observed a thickening of this region. By Western blot analysis, it was shown, and increment in the phosphorylation level of eNOS and PI3K/AKT/mTOR/p70S6K proteins in the heart of the (−)-epicatechin treated animals. On the other hand, we observed a significantly decreased level of the atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) heart failure markers. Conclusion: All the results indicate that (−)-epicatechin has the potential to prevent the development of dilated cardiomyopathy of genetic origin and encourages the use of this flavonol as a pharmacological therapy for dilated cardiomyopathy and heart failure diseases.
KW - (−)-epicatechin
KW - Dilated cardiomyopathy
KW - Fibrosis
KW - Sgcd null mice
KW - Vasoconstriction
UR - http://www.scopus.com/inward/record.url?scp=85051731339&partnerID=8YFLogxK
U2 - 10.1016/j.numecd.2018.06.019
DO - 10.1016/j.numecd.2018.06.019
M3 - Artículo
C2 - 30143409
SN - 0939-4753
VL - 28
SP - 1188
EP - 1195
JO - Nutrition, Metabolism and Cardiovascular Diseases
JF - Nutrition, Metabolism and Cardiovascular Diseases
IS - 11
ER -